Compare WVE & PRAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WVE | PRAA |
|---|---|---|
| Founded | 2012 | 1996 |
| Country | United States | United States |
| Employees | N/A | 170 |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 673.9M | 710.0M |
| IPO Year | 2015 | 2002 |
| Metric | WVE | PRAA |
|---|---|---|
| Price | $3.37 | $13.02 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 21 | 0 |
| Target Price | ★ $17.05 | N/A |
| AVG Volume (30 Days) | ★ 2.9M | 345.5K |
| Earning Date | 10-27-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.24 |
| Revenue | $3,704,000.00 | ★ $1,201,837,000.00 |
| Revenue This Year | $48.79 | $8.48 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.01 |
| Revenue Growth | ★ 149.43 | 7.83 |
| 52 Week Low | $3.04 | $10.25 |
| 52 Week High | $21.73 | $22.55 |
| Indicator | WVE | PRAA |
|---|---|---|
| Relative Strength Index (RSI) | 43.99 | 22.77 |
| Support Level | $3.04 | $10.29 |
| Resistance Level | $3.97 | $15.95 |
| Average True Range (ATR) | 0.24 | 1.15 |
| MACD | 0.05 | -0.36 |
| Stochastic Oscillator | 35.14 | 4.50 |
WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
PRA Group Inc is a specialty finance company engaged in the purchase, collection, and management of nonperforming loan portfolios. The majority of the loans it purchases are from credit originators who have chosen not to pursue, or have been unsuccessful in collecting, the full balance owed to them (Core accounts). To a lesser extent, the company also purchases loans in situations where the customer is involved in a bankruptcy or similar proceeding (Insolvency accounts). As part of an ancillary business, it also purchases and provides fee-based services for class action claims recoveries in the U.S. The company has two operating and reportable segments, comprised of its U.S. and European businesses. The majority of its revenue is generated from the United States.